Treatment and practical considerations of diabetic kidney disease
Open Access
- 1 December 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1264497
Abstract
Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease. In the early 90s, angiotensin blockade (ACEi and ARBs) was introduced, which revolutionized the treatment of DKD. In recent years, newer drugs such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin antagonists, and mineralocorticoid receptor antagonists (MRA) have shown great promise in reducing albuminuria and protecting the kidneys. These drugs are being used in combination with lifestyle modifications, patient education, and risk factor modification to effectively manage DKD. In this review, we will explore the latest pharmacological options, their efficacy, and their potential to revolutionize the management of this debilitating disease.Keywords
This publication has 97 references indexed in Scilit:
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialEuropean Heart Journal, 2013
- Central regulation of blood pressure by the mineralocorticoid receptorMolecular and Cellular Endocrinology, 2012
- Avosentan for Overt Diabetic NephropathyJournal of the American Society of Nephrology, 2010
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic NephropathyJournal of the American Society of Nephrology, 2009
- Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?European Respiratory Journal, 2009
- Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidenceEuropean Journal of Clinical Investigation, 2009
- The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shockActa Anaesthesiologica Scandinavica, 2008
- Use of ACE inhibitors and ARBs in hypertensive women of childbearing ageJournal of Clinical Pharmacy and Therapeutics, 2008
- Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 DiabetesDiabetes Care, 2007
- Antiproteinuric Effect of Captopril in Primary Glomerular DiseaseNephron, 1987